相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
Qinyu Yang et al.
FRONTIERS IN PHARMACOLOGY (2023)
Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication
Yi Hu et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
Min Niu et al.
FRONTIERS IN PHARMACOLOGY (2022)
2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment
Liya Zhou et al.
CHINESE MEDICAL JOURNAL (2022)
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
Hanxin Bi et al.
CHINESE MEDICAL JOURNAL (2022)
Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection A Meta-Analysis of Randomized Controlled Trials
Qiuyue Huang et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2021)
PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis
Cailing Li et al.
HELICOBACTER (2021)
Association of tobacco smoke-infused water (tuibur) use by Mizo people and risk of Helicobacter pylori infection
Subhajit Mukherjee et al.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2020)
The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors
Tianxiang Shen et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis
Cai-Ping Gao et al.
HELICOBACTER (2020)
Rabeprazole-amoxicillin dual therapy as first-line treatment forH pylorieradication in special patients: A retrospective, real-life study
Wen Gao et al.
HELICOBACTER (2020)
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-lineHelicobacter pyloriinfection eradication: A randomized trial
Zhiqiang Song et al.
HELICOBACTER (2020)
A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial
Wei-Chen Tai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment A systematic review and meta-analysis
Xue Yang et al.
MEDICINE (2019)
Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control
Hongyun Wang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States
Julia Butt et al.
GASTROENTEROLOGY (2019)
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions
Alessia Savoldi et al.
GASTROENTEROLOGY (2018)
Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
Wen Zhong Liu et al.
HELICOBACTER (2018)
EFFICACY OF HIGH-DOSE DUAL THERAPY VERSUS BISMUTH-CONTAINING QUADRUPLE THERAPY FOR FIRST-LINE TREATMENT OF HELICOBACTER PYLORI INFECTION AND AN INTERIM REPORT OF MULTI-CENTER, RANDOMIZED CONTROL STUDY
Chi-Tan Hu et al.
GASTROENTEROLOGY (2017)
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Carlo A. Fallone et al.
GASTROENTEROLOGY (2016)
Role of bismuth in improving Helicobacter pylori eradication with triple therapy
Maria Pina Dore et al.
GUT (2016)
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou et al.
LANCET (2016)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
Jyh-Chin Yang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for Helicobacter pylori Infections
Taraq A. Attumi et al.
HELICOBACTER (2014)
Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5
Kyung-Ah Seo et al.
XENOBIOTICA (2012)
High Efficacy of 14-Day Triple Therapy-Based, Bismuth-Containing Quadruple Therapy for Initial Helicobacter pylori Eradication
Qinjuan Sun et al.
HELICOBACTER (2010)
Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis
Alexander C. Ford et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease
AP Periclou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
